货号 | AF3606-SP |
别名 | FLJ42964; muscle and microspikes RAS; muscle RAS oncogene homolog; ras-related protein M-Ras; Ras-related protein R-Ras3; R-RAS3; RRAS3M-RAs |
反应种属 | Human/Rat |
应用 | Western Blot(2 µg/mL) |
目标/特异性 | Detects human and rat M-Ras/R-Ras3 in Western blots. Does not detect recombinant human R-Ras or TC21 (R-Ras2). |
使用方法 | Western Blot: 2 µg/mL |
来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
产品组分 |
供应商 | R&D Systems |
Entrez Gene IDs | 22808 (Human); 17532 (Mouse); 25482 (Rat) |
应用文献 | |
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells | |
纯化方式 | Antigen Affinity-purified |
免疫原 | E. coli-derived recombinant human M-Ras Met1-Leu208 (Lys181Glu) Accession # O14807 |
生物活性 | Human, Rat |
标记 | Unconjugated |
溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
背景 | Muscle Ras (M-Ras), also known as R-Ras3, is a small GTP-binding protein of the Ras superfamily of GTPases. M-Ras comprises an R-Ras subfamily with fellow members R-Ras and TC21 (R-Ras2). While highly homologous elsewhere, M-Ras differs at its carboxyl terminus from both R-Ras and TC21, suggesting this GTPase may interact with novel signaling effectors. |
运输条件 | Blue Ice |
存放说明 | 4℃ |
参考文献 |
|
Detection of Human and Rat M‑Ras/R‑Ras3 by Western Blot. Western blot shows lysates of L6 rat myoblast cell line. PVDF membrane was probed with 2 µg/mL Goat Anti-Human/Rat M‑Ras/R‑Ras3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3606) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). For additional reference, recombinant human R‑Ras, TC21/R-Ras2, and M‑Ras/R‑Ras3 (2 ng/lane) were included. A specific band for M‑Ras/R‑Ras3 was detected at approximately 24 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1. |